Lead

ing the

Leading the

Development of

Targeted Therapies in Cancer

Our team is dedicated to the development of innovative antibody treatments designed to challenge and revolutionize cancer care.

Explore our innovative science

Cutting-edge Therapeutic Solutions

We leverage scientific innovation and expertise to create groundbreaking first-in-class cancer treatments. We’re committed to not just fighting cancer, but also to improving the quality of life for patients.

Discovery of Novel Targets

We identify and explore novel targets based on academic excellence to develop new first-in-class treatment options.

Development of Drug Candidates

We develop therapeutics antibodies against cancer.

By combining expertise in recombinant antibody technology and state-of-the-art experimental models we provide proof-of-concept for novel treatment.

Collaboration Drives Progress

We believe in academic and industrial collaborations at an early stage.

By working with excellent partners, our projects are brought to the benetfit of patients in the fastest and most efficient way.

Learn More About Our Drug Development Programs

New targets are needed...

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths yearly, or nearly one in six deaths.

LB01

A novel target for checkpoint inhibition in leukemia and solid tumors.

LB02

A novel target selectively expressed on leukemic cells.

LB03

An innate immune checkpoint inhibitor.

...to efficiently treat where we fail today.

Discover with Lead Biologics